An older woman with white hair smiles in a green garden.

Tests

Which tests matter?

Before treatment is chosen, two things are examined closely: how far the cancer has spread and what features the tumour has. Here is what happens and what you can ask.

  • 6 min read
  • Updated 17 November 2026

Most important in brief

  • CT, PET-CT and a brain MRI show how far the cancer has spread.
  • A biomarker test looks in the tumour for features such as EGFR, ALK, KRAS G12C and PD-L1.
  • The result helps decide whether a targeted tablet or immunotherapy is suitable.
  • For advanced NSCLC, guidelines recommend testing several markers together, often with NGS.
  • Usually tissue from a biopsy is tested. A blood test can sometimes add information, and when a tablet stops working, testing is often repeated.
  • Only your care team can interpret your result. Bring your report and ask.

This page explains non-small cell lung cancer (NSCLC). Small cell lung cancer is tested and treated differently. Everything about it on its own page →

Tests for the stage

First it is worked out how far the cancer has spread. That decides whether surgery or radiotherapy aimed at cure is an option.

TestWhat it is for
CT and PET-CTBefore treatment
Show how far it has spread.
Brain MRIBefore treatment
Looks for spread to the brain, before treatment and at check-ups.
Lymph node sample (EBUS)Before treatment
Checks lymph nodes in the middle of the chest, often before surgery.
Lung function and heartBefore treatment
Show whether surgery would be well tolerated.

Why is the tumour tested?

Not every lung cancer is the same. A biomarker test looks in the tumour for features that can matter for treatment, such as PD-L1 and gene changes like EGFR, ALK or KRAS G12C. For advanced NSCLC, professional guidelines recommend testing several markers together where possible, often with NGS (ESMO; Onkopedia).

What your result can mean

This table shows the main markers in advanced NSCLC and what they can mean for treatment. Your care team will tell you what applies to you and what is available in your country.

ResultWhat it isWhat it can mean for treatment
EGFR
Mutation, about 1 in 7 in Europe
Targeted tablets, usually as the very first treatment, also after surgery.
ALK
Gene fusion, about 3 to 5 in 100
Targeted tablets as the first treatment, also after surgery.
ROS1
Gene fusion, about 1 to 2 in 100
Targeted tablets as the first treatment.
KRAS G12C
Mutation, about 1 in 7
Targeted tablets, in the EU after a first treatment.
BRAF V600E
Mutation, about 1 to 2 in 100
Two tablets together, often as the first treatment.
MET exon 14
Change (exon 14 skipping), about 3 in 100
Targeted tablets, in the EU after a first treatment.
RET
Gene fusion, about 1 to 2 in 100
Targeted tablet, often as the first treatment.
NTRK
Gene fusion, fewer than 1 in 100
Tablets authorised for any cancer with this fusion.
HER2
Mutation, about 2 to 3 in 100
An antibody medicine, in the EU after a first treatment.
Other KRAS forms
Mutation
No authorised tablet yet. Treated as if no change was found.
PD-L1
A protein on tumour cells, given as a percentage
Helps choose immunotherapy. 50% or more: also possible alone. 1 to 49%: usually together with chemo. Below 1%: possible with chemo; some immunotherapies require at least 1%.
None of these changes
Common
Usually immunotherapy, often together with chemotherapy.

Simplified, as of November 2026, based on the ESMO and Onkopedia guidelines. Frequencies are for people with NSCLC in Europe.

Usually only one of these changes is found, rarely two. The team then discusses which one counts first for treatment.

Changes found in about 4 in 100 people with NSCLC or more have their own page: EGFR, KRAS G12C, ALK. ROS1 shares the ALK page because it is very similar.

All others are explained in the same way on the Rarer changes page.

What kinds of test are there?

The test is done on a sample, and there are two ways of reading it. Your report says which were used for you.

TypeWhat is testedGood to know
Tissue sample (biopsy)
A small piece of tumour tissue
The usual way to test.
Blood sample (liquid biopsy)
Traces of the tumour in the blood
No new biopsy needed. If it finds nothing, there may still be something in the tissue.
Single-gene test
One gene or one feature
Several markers need several tests, so more tissue and time.
NGS panel
Many genes at once
Saves tissue and time when several markers are needed.

Tests at an early stage

Even when surgery is possible, biomarkers matter: with EGFR or ALK a tablet after surgery is an option, and immunotherapy beforehand then helps less. The PD-L1 level can matter for immunotherapy before or after surgery. Ask whether these tests were done, ideally before surgery.

A new test when treatment stops working

When a targeted tablet stops working, testing is often repeated, from tissue or blood. The test shows what has changed in the tumour, which decides what may help next.

TestWhat it is for
New test when the tablet stops workingDuring and after treatment
Tissue or blood shows what has changed and what may help next.
Blood test (liquid biopsy)Ask about it
Finds tumour DNA in the blood when there is not enough tissue or speed matters.

Reading your report: an example

Reports are often hard to read. This made-up example shows where the important details usually are. Each line comes with what it means.

Example · not a real reportMolecular pathology report

In the reportExampleWhat it means
Specimen
Tumour tissue, lung biopsy
Where the sample came from: tissue from a biopsy or operation, or blood.
Diagnosis
Adenocarcinoma of the lung (NSCLC)
The type of lung cancer. NSCLC is the umbrella term, adenocarcinoma the most common form.
Method
NGS panel, 50 genes
How the test was done. “NGS” or “panel” means many genes at once.
KRAS
p.G12C (c.34G>T)detected
The change was found. “p.G12C” and “c.34G>T” are two technical ways of writing the same change.
EGFR, ALK, ROS1
not detected
These changes were not found. That is an important result too.
PD-L1 (TPS)
30%
Share of tumour cells carrying the protein PD-L1. Your team will explain what the value means for you.
Made-up example. Real reports look different from lab to lab and may use other words.

Only your care team can say what your result means for your treatment. Take the report to your appointment and mark anything you don’t understand.

Questions to ask about tests

  • Why ask?

    If a marker is missing, a matching treatment can be overlooked.

  • Why ask?

    A single-gene test finds only what it looked for; a panel also finds rare changes.

  • Why ask?

    If there is not enough, a blood test or a new biopsy may be needed, which takes time.

  • Why ask?

    Then you know what you are waiting for and whom to contact.

  • Why ask?

    Not every test is paid for everywhere; this can be cleared up beforehand.

Sources

  1. ESMO Living Guideline: oncogene-addicted metastatic NSCLC
  2. Onkopedia: Lungenkarzinom, nicht-kleinzellig (NSCLC)

All sources last checked on 12 November 2026, unless another date is given.